Multiple sclerosis and pregnancy: experience from a nationwide database in Germany

Objective: The objective of this study was to evaluate exposure to disease-modifying therapies (DMTs) during pregnancy in 335 pregnancies of multiple sclerosis (MS) patients and to further determine whether exclusive breastfeeding of MS mothers has any relevant influence on postpartum relapse rate....

Full description

Bibliographic Details
Main Authors: Kerstin Hellwig, Aiden Haghikia, Milena Rockhoff, Ralf Gold
Format: Article
Language:English
Published: SAGE Publishing 2012-09-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285612453192
_version_ 1818505113968312320
author Kerstin Hellwig
Aiden Haghikia
Milena Rockhoff
Ralf Gold
author_facet Kerstin Hellwig
Aiden Haghikia
Milena Rockhoff
Ralf Gold
author_sort Kerstin Hellwig
collection DOAJ
description Objective: The objective of this study was to evaluate exposure to disease-modifying therapies (DMTs) during pregnancy in 335 pregnancies of multiple sclerosis (MS) patients and to further determine whether exclusive breastfeeding of MS mothers has any relevant influence on postpartum relapse rate. Background: Only limited data are available on whether DMT exposure during pregnancy affects relapse rate during pregnancy or after birth. Currently, findings on beneficial effect of exclusive breastfeeding on MS disease course are controversially discussed. Methods: We enrolled pregnant women with MS who contacted us directly or via their treating physicians to be included in our nationwide MS and pregnancy database. Results: We identified 78 pregnancies under interferon-beta (IFNβ) preparations, 41 under glatiramer acetate (GLAT), and 216 pregnancies without DMT exposure during pregnancy. As expected, annualized relapse rate (ARR) decreased continuously during pregnancy in nonexposed mothers ( p < 0.001) to then increase after birth. In IFNβ- or GLAT-exposed women this typical pattern was not as obvious. Congenital anomalies were within normal ranges in exposed pregnancies. In total, 170 women were identified who exclusively breastfed (EBF). Significantly reduced postpartum relapse rate during the first 3 months after birth were registered in the EBF group as compared with nonexclusively breastfeeding (NEBF) or nonbreastfeeding women (NBF) women with MS ( p < 0.0001). Relapse rate (RR) in the year before pregnancy had been similar throughout all groups. We did not observe any significant differences in RR of NEBF and NBF women. Conclusion: Exclusive breastfeeding showed some beneficial effects on postpartum relapse rate in our cohort. Our data support that IFNβ and GLAT do not seem to represent a major teratogenic risk in pregnancy.
first_indexed 2024-12-10T21:46:19Z
format Article
id doaj.art-33619cc7981f4304b92762f71530d97d
institution Directory Open Access Journal
issn 1756-2856
1756-2864
language English
last_indexed 2024-12-10T21:46:19Z
publishDate 2012-09-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Neurological Disorders
spelling doaj.art-33619cc7981f4304b92762f71530d97d2022-12-22T01:32:21ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642012-09-01510.1177/1756285612453192Multiple sclerosis and pregnancy: experience from a nationwide database in GermanyKerstin HellwigAiden HaghikiaMilena RockhoffRalf GoldObjective: The objective of this study was to evaluate exposure to disease-modifying therapies (DMTs) during pregnancy in 335 pregnancies of multiple sclerosis (MS) patients and to further determine whether exclusive breastfeeding of MS mothers has any relevant influence on postpartum relapse rate. Background: Only limited data are available on whether DMT exposure during pregnancy affects relapse rate during pregnancy or after birth. Currently, findings on beneficial effect of exclusive breastfeeding on MS disease course are controversially discussed. Methods: We enrolled pregnant women with MS who contacted us directly or via their treating physicians to be included in our nationwide MS and pregnancy database. Results: We identified 78 pregnancies under interferon-beta (IFNβ) preparations, 41 under glatiramer acetate (GLAT), and 216 pregnancies without DMT exposure during pregnancy. As expected, annualized relapse rate (ARR) decreased continuously during pregnancy in nonexposed mothers ( p < 0.001) to then increase after birth. In IFNβ- or GLAT-exposed women this typical pattern was not as obvious. Congenital anomalies were within normal ranges in exposed pregnancies. In total, 170 women were identified who exclusively breastfed (EBF). Significantly reduced postpartum relapse rate during the first 3 months after birth were registered in the EBF group as compared with nonexclusively breastfeeding (NEBF) or nonbreastfeeding women (NBF) women with MS ( p < 0.0001). Relapse rate (RR) in the year before pregnancy had been similar throughout all groups. We did not observe any significant differences in RR of NEBF and NBF women. Conclusion: Exclusive breastfeeding showed some beneficial effects on postpartum relapse rate in our cohort. Our data support that IFNβ and GLAT do not seem to represent a major teratogenic risk in pregnancy.https://doi.org/10.1177/1756285612453192
spellingShingle Kerstin Hellwig
Aiden Haghikia
Milena Rockhoff
Ralf Gold
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
Therapeutic Advances in Neurological Disorders
title Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
title_full Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
title_fullStr Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
title_full_unstemmed Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
title_short Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
title_sort multiple sclerosis and pregnancy experience from a nationwide database in germany
url https://doi.org/10.1177/1756285612453192
work_keys_str_mv AT kerstinhellwig multiplesclerosisandpregnancyexperiencefromanationwidedatabaseingermany
AT aidenhaghikia multiplesclerosisandpregnancyexperiencefromanationwidedatabaseingermany
AT milenarockhoff multiplesclerosisandpregnancyexperiencefromanationwidedatabaseingermany
AT ralfgold multiplesclerosisandpregnancyexperiencefromanationwidedatabaseingermany